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Background: Hepatic resection for metastatic colorectal 
cancer provides excellent longterm results in a substan-
tial proportion of patients. Although various prognostic 
risk factors have been identified, there has been no de-
pendable staging or prognostic scoring system for met-
astatic hepatic tumors. 
Study Design: Various clinical and pathologic risk fac-
tors were examined in 305 consecutive patients who 
underwent primary hepatic resections for metastatic 
colorectal cancer. Survival rates were estimated by the 
Cox proportional hazards model using the equation: 
Set) = [So(t)]exp(R- R..), where So(t) is the survival rate 
of patients with none of the identified risk factors and 
Ro=O. 
Results: Preliminary multivariate analysis revealed that 
independently significant negative prognosticators 
were: (1) positive surgical margins, (2) extrahepatic tu-
mor involvement including the lymph node(s), (3) tu-
mor number of three or more, (4) bilobar tumors, and 
(5) time from treatment of the primary tumor to hepatic 
recurrence of 30 months or less. Because the survival 
rates of the 62 patients with positive margins or extra-
hepatic tumor were uniformly very poor, multivariate 
analysis was repeated in the remaining 243 patients who 
did not have these lethal risk factors. The reanalysis 
revealed that independently significant poor prognosti-
cators were: (1) tumor number of three or more, (2) 
tumor size greater than 8cm, (3) time to hepatic recur-
. rence of30 months or less, and (4) bilobar tumors. Risk 
scores (R) for tumor recurrence of the culled cohort 
(n = 243) were calculated by summation of coefficients 
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from the multivariate analysis and were divided into five 
groups: grade 1, no risk factors (R = 0); grade 2, one risk 
factor (R= 0.3 to 0.7); grade 3, two risk factors (R= 0.7 
to 1.1); grade 4, three risk factors (R= 1.2 to 1.6); and 
grade 5, four risk factors (R> 1.6). Grade 6 consisted of 
the 62 culled patients with positive margins or extrahe-
patic tumor. Kaplan-Meier and Cox proportional haz-
ards estimated 5-year survival rates of grade 1 to 6 pa-
tients were 48.3% and 48.3%, 36.6% and 33.7%, 
19.9% and 17.9%,11.9% and 6.4%, 0% and 1.1 %, and 
0% and 0%, respectively (p < 0.0001). 
Conclusions: The proposed risk-score grading predicted 
the survival differences extremely well. Estimated sur-
vival as determined by the Cox proportional hazards 
model was similar to that determined by the Kaplan-
Meier method. Verification and further improvements 
of the proposed system are awaited by other centers or 
international collaborative studies. (J Am CoIl Surg 
1999;189:291-299. © 1999 by the American College 
of Surgeons) 
Hepatic resection for metastases from colorectal 
carcinoma can be performed quite safely and pro-
vides excellent longterm results in a substantial 
proportion of patients. 1-18 Now that various clini-
cal and pathologic risk factors have been 
identified,I-18 the efforts of investigation should be 
shifted to establishing an accurate staging system 
for metastatic hepatic tumors or a dependable 
prognostic scoring method to predict the results 
after curative operations. 
291 
We examined our 305 consecutive patients with 
colorectal metastases who underwent hepatic resec-
tion with curative intent to identify clinical and 
pathologic prognosticators. We propose here a new 
prognostic scoring methoQ and associated propor-
tional hazards model for survival. 
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METHODS 
Patients and tumors 
During the IS-year period between 1981 and 1996, 
305 consecutive patients were treated with primary 
hepatic resection for hepatic metastases from adeno-
carcinoma of colorectal origin at the University of 
Pittsburgh Medical Center. All hepatic resections 
were carried out with curative intent. There were 178 
men and 127 women. Their ages ranged from 26 to 
82 years (mean ± SE 60 ± 0.6 years). 
The primary tumor was located in the right co-
lon of 71 patients (23.3%), the left colon of 156 
(51.1 %), and the rectum of 78 (25.6%). Five pa-
tients (1.6%) had Dukes A (stage I) primary tumors 
and 70 (23.0%) had Dukes B (stage II). Dukes C 
(stage III) tumors represented the largest group with 
141 patients (46.2%); 89 patients (29.2%) had syn-
chronous hepatic metastases (Dukes D; stage IV). 19.20 
Most patients with Dukes D tumors underwent he-
patic resection within the first 3 months after their 
colorectal resection. Twenty-three patients were not 
referred or evaluated until after this interval. Metas-
tases to the mesenteric lymph nodes were present at 
the time of colorectal operation in 154 patients 
(50.5%) and were absent in 148 (48.5%). The status 
of lymph node involvement was not available in 
three patients. 
The interval between the primary colorectal re-
section and hepatic resection ranged from - 6 
months (primary not discovered until after resection) 
to 228 months, with a median of 16 months. 
One hundred thirty-seven patients (44.9%) had 
solitary lesions, 75 (24.6%) had 2 lesions, 31 
(10.2%) had 3 lesions, and 62 (21.0%) had 4 or 
more lesions (as many as 11). The size of the hepatic 
metastasis ranged from 1.2 to 18 cm with a median of 
5 cm; the size exceeded 8 cm in 48 (15.7%) of the 305 
patients. The hepatic metastases were unilobar in 
200 patients (65.6%) and bilobar in the other 105 
(34.4%). 
At the time of hepatic resection, abdominal 
lymph node metastases were present in 9 patients 
(3.0%) and absent in 296 (97.0%). Because of direct 
tumor invasion, the diaphragm, the right adrenal 
gland, the greater omentum, or localized peritoneal 
seeding were removed in continuity with the resected 
liver in 32 patients (10.5%). 
The metastatic tumors were histologically well 
differentiated (grade 1) in 59 patients (19.3%), 
moderately differentiated (grade 2) in 239 
(78.4%), and poorly differentiated (grade 3) in 7 
(2.3%).18.19 
Right or left hepatic lobectomy was performed in 
158 patients, more than lobectomy (trisegmentec-
tomy, extended lobectomy, and lobectomy plus 
wedge resection) in 85 patients, multiple bilateral 
wedge resections in 20 patients, and less than lobec-
tomy (left lateral segmentectomy and nonanatomic 
resection) in 42 patients. Of note, 243 (79.7%) of 
the 305 patients were treated by lobectomy or greater 
hepatic resection. Despite the curative intent of re-
section, 28 (9.2%) of the 305 patients had micro-
scopically positive margins at postoperative patho-
logic examinations, although all gross tumors were 
removed. 
After hepatic resection with curative intent, 202 
(66.2%) of the 305 patients received adjuvant che-
motherapy. Although no single chemotherapeutic 
protocol was applied, the usual regimen contained 
5-FU with levamisole or leucovorin for 6 months. 
Recurrent tumors after hepatic resection were surgi-
cally removed in 32 patients, including 12 thoraco-
scopic pulmonary resections, 11 hepatic re-
resections, 3 bone resections (2 sacrum, 1 sternum), 
3 abdominal-wall resections, 1 adrenalectomy, and 2 
colectomies. 
Data analysis 
We retrospectively reviewed all available inpatient 
and outpatient records, including operative and 
pathologic reports. Patient followup was per-
formed prospectively every 6 months after hepatic 
resection, and the results were summarized as of 
June 30, 1998. The median followup period was 
32 months. 
The 16 clinical and pathologic risk factors listed 
in Table 1 were examined for prognostic influence. 
Patient survival time was calculated from the date of 
hepatic resection until death, and tumor-free survival 
was determined from the date of resection until the 
time of tumor recurrence. Survival curves were 
generated with the method of Kaplan and Meier 
and were compared using the log-rank test. A mul-
tivariate stepwise Cox regression analysis (back-
ward elimination method) was performed to iden-
tify the factors that were independently associated 
with mortality and tumor recurrence. A two-sided 
p value of < 0.05 was considered statistically 
significant. 
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Table 1. Influences of Various Clinical and Pathologic Risk Factors on Overall Patient and Tumor-Free Survival 
Overall patient survival Tumor-free survival 
P p 
Characteristic n 3 y (%) 5 y (%) 10 y (%) Value 3 y (%) 5 y (%) 10 y (%) Value 
Patient 
Gender 
Male 178 49.3 33.5 24.7 NS 34.9 28.2 24.7 <0.03 
Female 127 47.1 30.5 23.3 26.4 15.7 13.5 
Age (y) 
=560 143 51.S 36.5 28.6 NS 32.1 23.8 21.0 NS 
>60 . 162 46.6 28.2 19.0 30.S 22.3 18.8 
Primary tumor 
Site 
Rectum 78 SO.l 40.5 31.1 NS 37.6 26.0 21.4 NS 
Left colon 156 50.8 30.9 20.0 31.S 22.0 18.6 
Right colon 71 41.2 26.4 24.2 23.6 21.6 21.6 
Dukes classification 
A+B 7S 60.3 44.9 31.5 NS 39.9 28.8 28.8 <0.06 
C 141 42.8 27.4 21.5 27.4 19.9 18.8 
D (synchronous) 89 47.1 28.6 20.9 30.4 22.8 14.7 
Dukes classification 
A+B 75 60.3 44.9 31.5 <0.053 39.9 28.8 28.8 <0.002 
C+D 230 44.6 28.1 21.8 28.4 20.9 16.8 
Lymph node 
Negative 148 56.9 36.8 27.3 <0.03 35.9 25.9 24.7 <0.02 
Positive 154 39.9 27.7 21.3 26.7 20.5 16.6 
Hepatic metastases 
Interval (mo) 
=5 12 132 48.8 28.7 25.1 NS 28.8 24.0 21.9 NS 
12-24 77 38.8 30.9 20.7 25.1 19.7 17.5 
25-36 42 48.1 40.5 21.6 34.2 15.4 7.7 
3H8 22 65.7 23.6 23.6 40.0 21.0 21.0 
>48 32 58.2 45.8 32.8 47.0 37.6 32.3 
Interval (mo) 
=530 235 44.6 29.9 22.5 <0.04 27.6 20.9 18.2 <0.01 
>30 70 61.4 40.1 29.6 43.3 29.3 26.4 
No. of tumors 
1 137 57.3 41.4 32.3 <0.001 40.9 33.1 31.0 <0.0001 2 75 50.6 37.6 24.9 35.0 22.8 17.8 
3 31 38.4 11.7 19.4 14.5 
;;::4 62 31.4 16.1 10.7 11.9 5.0 
No. of tumors 
1-2 212 55.0 40.2 29.8 <0.0001 38.8 29.4 26.3 <0.0001 ;;::3 93 33.8 14.6 11.2 14.4 8.1 
Size (em) 
=52 15 58.2 43.6 29.1 NS 46.7 46.7 46.7 NS 
2-5 152 51.0 32.0 23.4 31.8 25.1 21.7 
5-10 102 45.8 34.4 26.3 29.6 17.7 15.8 
>10 31 39.9 20.7 1S.4 27.8 17.4 11.6 
Size (em) 
=58 257 50.9 34.6 25.5 <0.03 33.5 24.9 22.0 <0.02 
>8 48 34.7 19.3 16.1 18.8 11.7 7.8 
Distribution 
Unilobar 200 56.0 39.2 29.2 <0.0001 38.0 28.7 26.0 <0.0001 
Bilobar 105 33.8 18.9 13.9 18.2 11.7 8.9 
(Table 1 continues on ncxt page) 
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Table 1. Continued 
~rrulpatientsunnv.U Tumor-free sunrival 
Characteristic n 3 y(%) 5 y(%) 10 y (%) 
Node metastasis 
No 296 49.5 32.9 24.5 
Yes 9 11.1 
Metastasis 
No 273 51.1 34.6 26.2 
Yes 32 20.8 5.5 0 
Differentiation 
Grade 1 59 50..4 39.6 32.1 
Grade 2 239 48.1 30.2 21.8 
Grade 3 7 42.9 28.6 
Surgery 
Margin 
>lcm 130 54.2 38.4 26.7 
:51cm 147 48.4 31.4 25.8 
Involved 28 20.9 8.4 0 
Resection 
Multiple wedges 20 38.9 13.0 0 
More chan lobe 85 33.3 21.1 19.3 
Lobectomy 158 54.7 37.2 25.3 
Less than lobe 42 57.5 40.6 34.8 
Adjuvant therapy 
No 103 44.4 33.6 23.0 
Yes 202 50.4 31.3 24.5 
Surgery for recurrence 
No 197 27.0 7.7 0.9 
Yes 32 87.5 77.2 52.2 
RESULTS 
Early mortality and morbidity 
Ther~ were no. deaths within the first 30 days after 
h~pa~lc resectlon, although three patients died 
WIthIn 90 days (perioperative mortality of less than 
1 ~o). One death was in a 71-year-old man after right 
trlsegmentectomy who developed liver failure and 
stress-ulcer bleeding. Two other deaths from liver 
failure and septicemia after extended right lobectomy 
were in 62- and 67-year-old men. 
.. In ~ddit~on, there were 16 cases of severe hyper-
bilirubmemia (serum total bilirubin greater than 
8 mg/l 00 mL), 7 subphrenic abscesses, 5 cases of pro-
longed ascites or pleural effusion, 2 deep vein throm-
boses, 2 prolonged bile leaks, 2 cardiac arrhythmias, 
and 1 stress ulcer with bleeding. These complications 
occurred in 25 (8.2%) of the 305 patients (one pa-
tient had multiple complications) and were resolved 
without permanent consequences. 
Survival 
As of}une 30,1998,198 (64.9%) of the 305 patients 
were known to be dead with tumor recurrence, 12 
p p 
Value 3 y(%) 5 y(%) 10 y(%) Value 
<0.007 31.9 23.4 20.4 <0.05 
11.1 
<0.0001 34.5 25.3 22.9 '<0.0001 
0 0 0 
NS 39.4 28.1 28.1 NS 
29.2 22.0 17.4 
28.6 14.3 0 
<0.003 38.5 28.9 27.0 <0.0008 
30.2 22.2 18.1 
4.8 0 0 
<0.03 16.0 0 0 <0.006 
17.1 15.4 13.7 
36.6 24.8 22.9 
41.1 37.6 26.9 
NS 33.4 24.2 24.2 NS 
30.3 22.4 18.2 
<0.0001 8.6 2.5 0 <0.002 
30.2 6.7 3.4 
(3.9%) were dead without tumor recurrence, 67 
(22.0%) were alive and free of tumor recurrence, and 
28 (9.2%) were alive with tumor recurrence. None of 
the patients were lost to followup. Ten-year overall 
and tumor-free Kaplan-Meier survival curves for the 
305 patients after hepatic resection are depicted in 
Figure 1; 5-year overall survival was 32.3%. The 
tumor-free survival at this milestone was 23.0%. 
Examinations of clinical and pathologic risk factors 
The influences of 16 clinical and pathologic risk fac-
tors on overall patient and tumor-free survival rates 
w.ere examined (Table 1). For both end points, a sig-
nificantly better prognosis was associated with the 
following: (1) primary colorectal cancer of Dukes A 
and B, (2) no metastasis to the mesenteric lymph 
nodes at the time of colorectal operation, (3) interval 
between colorectal operation and hepatic resection of 
longer than 30 months, (4) cwo or fewer hepatic 
metastases, (5) greatest tumor diameter of Scm or 
less, (6) unilobar distribution of hepatic metastases, 
(7) no nodal metastasis at the time of hepatic resec-
tion, (8) no distant metastasis at the time of hepatic 
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resection, (9) microscopically negative surgical mar-
gins, and (10) lobectomy or smaller hepatic 
resectlon. 
The patients whose recurrent hepatic metastases 
could be resected surgically lived longer than those 
whose recurrent tumors were not resected. Although 
overall patient survival was similar for men and 
women, tumor-free survival for men was signifi-
cantly better than that for women (Table 1). 
Multivariate analysis 
Multivariate analysis based on the 305 patients iden-
tified the following significant poor prognosticators 
for overall and tumor-free survival: (1) positive sur-
gical margins, (2) extrahepatic metastasis including 
lymph nodes, (3) tumor number of three or more, (4) 
bilobar distribution of hepatic metastases, and (5) 
interval between colorectal resection and hepatic re-
section of 30 months or less. 
Because the survival of the 62 patients who had 
positive surgical margins and extrahepatic metastasis 
(including lymph nodes) was uniformly poor, uni-
variate and multivariate analyses were repeated after 
excluding these 62 patients to identify the indepen-
dent factors that could be used to calculate a risk 
score. The repeat univariate analysis on the remain-
ing 243 patients confirmed the significant effect of 
all previously discovered risk factors except for the 
status of the mesenteric lymph nodes at the time of 
colorectal operation (p > 0.17). The lymph node sta-
tus at the time of colorectal operation was better 
represented by Dukes classification (positive mesen-
teric lymph nodes are limited to Dukes C and D). 
The remaining six risk factors (size, number, lobar 
distriburion, time to recurrence, Dukes classifica-
tion, and extent of resection) met the assumption of 
proportionality of hazards by assessment of log-
minus-log survival plot. 
A stepwise Cox regression analysis with back-
ward selection was used to determine independent 
predictors of mortality and tumor recurrence. The 
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Figure 1. Ten-year overall patient and rumor-free Kaplan-Meier 
survival. 
likelihood ratio test based on maximum partial like-
lihood estimates was used for elimination of con-
founding variables from the model. Variables were 
considered eligible for removal if the likelihood ratio 
test significance level was :::::: 0.1. Four variables (tu-
mor number greater than two, tumor size greater 
than 8 em, interval of 30 months or less, and bilobar 
metastases) were found ro be independent predictors 
of tumor recurrence (Table 2). The results of the 
multivariate analysis for overall patient survival are 
shown in Table 3. The exclusion of Dukes classifica-
tion can be explained by the strong inverse relation 
(p < 0.000 1) between the time to recurrence (inter-
val) and Dukes stages (the shorter the interval, the 
more advanced the Dukes stage). The extent of he-
patic resection is an immediate consequence of the 
size, number, and distriburion of metastases, which 
explains its exclusion from a set of independent 
predictors. 
Table 2. Significant Prognostic Risk Factors for Tumor Recurrence (Tumor-Free Survival) 
Identified by Multivariate Analysis* 
Risk factor 
Tumor number> 2 
Tumor size> Bcm 
Interval ::::; 30 mo 
Bilobar rumors 
Coefficient (B) 
0.6286 
0.4724 
0.3894 
0.3308 
Relative risk 
1.87 
1.60 
1.48 
\.39 
·E.xcludes [he (,2 pltients with positive surgical mlrgins. lYmph node invasion. or disllnt metastas.s. 
95% Confidence 
interVal 
1.33-2.64 
1.06-2.43 
1.00-2.18 
0.98-1.97 
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Table 3. Significant Prognostic Risk Factors for Mortality (Overall Patient Survival) Determined 
by Multivariate Analysis* 
95% Confidence 
Risk factor Coefficient (B) Relative risk interval 
Tumor number> 2 0.5514 1.74 1.21-2.50 
Tumor size> 8cm 0.4006 1.49 0.96-2.32 
Interval ~ 30 mo 0.2585 1.29 0.87-1.93 
Bilobar tumors 0.2256 1.25 0.86-1.82 
'Excludes the 62 patients with positive surgical margins, lymph node invasion, or distant metastasis. 
Calculation of risk score and prediction of survival 
Based on the results of the multivariate analysis, the 
risk score can be calculated for each patient by the 
following formula: Risk score (R) = BIXI + B2X2 + 
B3X3 + B4X4, where B = coefficient from the Cox 
model (Tables 2, 3) and ~ = 0 when the risk factor is 
absent or ~ = 1 when the risk factor is present. 
Correspondingly, the probability of which pa-
tient with risk score R will be recurrence-free t years 
after hepatic resection (S(t)) can be calculated by the 
following;l: S(t) = [So(t)]exp(R-R,,), where R is the 
. 0 
nsk score corresponding to the baseline survival 
function So(t). Because all of the four risk factors are 
presented as binary variables, So(t) was calculated for 
a patient with no risk factors. The cumulative tumor-
free survival (Kaplan-Meier) of the 243 patients was 
then compared with the predicted probability of co-
hort tumor-free survival after hepatic resection (S(t»). 
The fit of the developed model was assessed heuris-
tically by comparison of overall patient and tumor-
free survival rates estimated by the Kaplan-Meier 
method versus the predicted survival by the Cox 
model of probability for various patient risk groups. 
As shown in Table 4, Set) agrees reasonably well with 
tumor-free survival as determined by the Kaplan-
Meier method. 
Practical application of risk score 
Risk scores for tumor-free survival were grouped into 
the following strata: grade 1, none of the four risk 
factors present (risk score = 0); grade 2, one of the 
four risk factors present (risk score = 0.3308 to 
0.6286); grade 3, two of the four risk factors present 
(risk score = 0.7202 to l.10 1); grade 4, three of the 
Table 4. Tumor-Free Survival Prediction * 
Prediction 
Actuarial (Kaplan-Meier) 
So(t) (estimated) 
ly 
72.3 
87.3 
2y 
46.9 
47.2 
3y 
38.4 
39.3 
4y 
four risk factors present (risk score = 1.1926 to 
1.4904); grade 5, all of the four risk factors present 
(risk score = 1.8212); and grade 6, positive surgical 
margins and lymph node or distant metastasis. 
Tumor-free survival rates (Kaplan-Meier) for the 
above-defined six grades of patients are depicted in 
Figure 2, and the tumor-free survival rates calculated 
by Set) (Cox model) are shown in Figure 3 for com-
parison. Note that the survival curves were similar. 
Overall patient survival rates (Kaplan-Meier) of 
the six grades of patients and those calculated by Set) 
are shown in Figures 4 and 5, respectively. 
DISCUSSION 
Hepatic resection for metastatic colorectal cancer can 
now be performed with minimal surgical risks. With 
this treatment, an overallS-year survival rate of25% 
to 40% has been commonly achieved. l.ls Various fac-
tors influencing outcomes have been reported in the 
literature. I-IS Positive surgical margins, lymph node 
invasion, and distant metastasis have proved to be 
prognosticators for failure in all studies. The stages of 
primary colorectal cancer (TNM stage, Dukes clas-
sification, or status of mesenteric lymph nodes at the 
time of colorectal resection); the size, number, and 
lobar distribution of hepatic metastases; and the time 
from colorectal resection to hepatic metastasis (syn-
chronous versus metachronous) have been identified 
as significant prognostic determinants. In some stud-
ies. blood transfusion during hepatectomy, type of 
hepatic resection. histologic grades of primary and 
metastaric tumors, serum CEA levels, and gender 
have been found to be significant. Repeared hepatic 
Sy 6y 7y 8y 9y lOy 
33.6 
30.6 
28.5 
26.6 
26.7 
26.6 
26.7 
26.6 
25.8 
26.6 
24.9 
26.6 
24.9 
26.6 
·Tumor·free survIval prediccion based on patients with no risk iactors ,S,,(t)) corrd3ted well wirh 3ccuariai tumor-f",., survival (Kaplan-Meier!. 
Data are presented as percentages. 
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Figure 2. Kaplan-Meier tumor-free survival stratified by six grades. 
resection for recurrent metastases has been reported 
to prolong overall survival. 22,23 
In our univariate analyses, 10 of the 16 variables 
studied were significantly associated with overall pa-
tient and tumor-free survival (Table 1). Although our 
findings agree in general with others,I-18 some of the 
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individual variables that were significant in our in-
vestigation were not in several other studies. Except 
for gender,S none of the prognosticators noted in the 
univariate analysis have been reported in other stud-
ies to have an opposite association from the ones that 
we saw. Differences between our study and others are 
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Figure 5. Estimated (Cox regression model) overall patient survival 
stratified by five grades (grade 6 cannot be estimated with this model). 
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mostly due to differences in the number of patients, 
length of followup, and grouping of continuous 
variables. 
The proposed formula derived from our current 
study (S(t) = So(t)]exp(R- R,l) appears to be simple 
and practical. It reflected reasonably well both 
tumor-free survival (Figs. 2, 3) and over<tll patient 
survival (Figs. 4, 5). 
Two other prognostic scoring systems for pa-
tients with hepatic metastases from colorectal carci-
noma have been reported in the literature. The one 
proposed by Cady and Stone in 1991 included sur-
gical margins, the time to hepatic recurrence, the 
number of metastases, and serum CEA levels. Be-
cause this scoring system was not based on statistical 
analyses, it could not be compared with ours. The 
second scoring system, advanced in 1996 by Nor-
dinger and associates13 on behalf of a French surgical 
consortium, was based on the study of 1 ,568 patients 
collected from 85 institutions over the last 3 decades. 
The following seven factors were found to be signif-
icant by multivariate analysis: (1) age (60 or older 
versus less than 60 years), (2) serosal involvement of 
primary tumor, (3) peritumorallymph node invasion 
by the primary, (4) time to hepatic recurrence (more 
than 2 years versus 2 years or less), (5) tumor size 
(greater than 5cm versus 5cm or less), (6) number of 
tumors (four or more versus fewer than four), and (7) 
surgical margins (1 em or more versus less than 1 em). 
The patients were classified into three categories, 
each with significantly poorer survival: grade 1, zero 
to two risk factors; grade 2, three to four risk factors; 
and grade 3, five to seven risk factors. This system 
was applied to our 144 patients with the best prog-
nosis (ie, those with our Pittsburgh grades 1 and 2). 
Our results with patients in grades 1 and 2 were 
essentially identical to those of the French13 grade 1 
patients. Only 55 (38.2%) of these patients qualified 
for a French grade 1, however. The French grading 
system 13 failed to identify more than 60% of the 
patients with the most hopeful prognosis according 
(Q our Pittsburgh system. 
The failure of the French grading system (Q ac-
curately predict the prognosis of our patients, and 
especially those with Pittsburgh grades 1 and 2, may 
be related to several factors identifiable in the report 
by Nordinger and associates lJ : (1) The twO closely 
linked factors of serosal involvement and peritu-
moral lymph node invasion were designated as inde-
pendent predictors in the French study by stepwise 
multivariate analysis; (2) a positive surgical margin 
was assumed if the tumor-free margin was less than 
1 em, inevitably excluding from the French grade 1 
patients with negative and positive margins; (3) ac-
crual of patients in the French study took place over 
3 decades but was not analyzed by era; (4) the insti-
tutional factor (85 centers) was not examined24; (5) 
more than 200 patients (including those with oper-
ative death) were excluded from the study; (6) age 
was not found to be a significant factor (p> 0.05); 
and (7) death without recurrence was not censored in 
the calculation of tumor-free survival but was con-
sidered as death with recurrence. 
When the French group reanalyzed the factors 
influencing 5-year survival, using the same database 
as in their previous report,15 they found only three 
factors that influenced the 5-year survival: serosa in-
filtration, peri tumoral lymph nodes, and surgical 
margin of less than 1 cm. The factors of age, time to 
hepatic recurrence, tumor size, and the number of 
metastases did not significantly influence survival at 
5 years. 
In view of these disparities between our scoring 
system and the French system,13 our Pittsburgh 
survival-prediction formula will have to be validated 
by other large series of patients. It is possible that 
refinements will be needed before it can be accepted 
universally. An international collaborative study by 
major centers could quickly accomplish this objec-
tive. Until then, our results indicate the following. 
First, excellent survival or even cure can be expected 
in more than one third of the patients with hepatic 
metastases if none or only one of the four risk factors 
is present (tumor number of three or more, bilobar 
tumors, tumor size greater than 8 em, and time to 
hepatic recurrence of 30 months or less). Second, the 
prognosis is extremely poor when all of the four risk 
factors are present, when extrahepatic metastasis in-
cludes the lymph nodes, or when the surgical mar-
gins are positive after hepatic resection. 
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